Skip to main content
Clinical Trials/NCT02072837
NCT02072837
Completed
Not Applicable

Dyslipidemia-related Variables as Risk Factor for Cardiovascular Disease in Patients on the End-stage of Renal Disease

National and Kapodistrian University of Athens0 sites96 target enrollmentJanuary 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Renal Disease
Sponsor
National and Kapodistrian University of Athens
Enrollment
96
Primary Endpoint
Associations between dyslipidemia with cardiovascular disease on patients on renal replacement therapy
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

In this study, we studied lipoprotein abnormalities-related variables as risk factors for the development of cardiovascular disease in patients on renal replacement therapies.We studied 96 dialyzed patients, 62 males and 34 females, on mean age 62.1 years old and 24 healthy controls.We concluded that metabolic acidosis activating the inflammation and lipoprotein oxidation influences the dyslipidemia and cardiovascular morbidity of patients on renal replacement therapies.Dialysis adequacy was positively associated to cardioprotective HDL.Peritoneal dialysis holds a better acidosis level and lower oxidized lipids than hemodialysis modalities.

Detailed Description

Blood samples were obtained by venipuncture in the peritoneal dialyzed patients and control group in a twelve hours fasting state.In hemodialyzed patients blood was drawn just before the start of the mean weekly dialysis session also in a twelve hours fasting state from the vascular access. All samples were received once at baseline time ( in the start of the study ). Peripheral systolic and diastolic blood pressures were calculated as an average of 10 measurements during a renal replacement treatment month in the starting time of the study. Also, electrocardiographic examination, echocardiography and the calculation of ankle-brachial blood pressure index became once in the start of the study.

Registry
clinicaltrials.gov
Start Date
January 2012
End Date
January 2014
Last Updated
12 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Vaia D.Raikou

Ph.D Nephrologist; Researcher

National and Kapodistrian University of Athens

Eligibility Criteria

Inclusion Criteria

  • permanent renal replacement therapy more than 6 months and
  • accurate dry body weight

Exclusion Criteria

  • acute illness,
  • significant infection,
  • malignancy,
  • Kt/V for urea \<1.2.

Outcomes

Primary Outcomes

Associations between dyslipidemia with cardiovascular disease on patients on renal replacement therapy

Time Frame: February 2014

Similar Trials